Biren Saraiya

780 total citations
59 papers, 385 citations indexed

About

Biren Saraiya is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Biren Saraiya has authored 59 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 18 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Biren Saraiya's work include Palliative Care and End-of-Life Issues (16 papers), Prostate Cancer Treatment and Research (15 papers) and Renal cell carcinoma treatment (12 papers). Biren Saraiya is often cited by papers focused on Palliative Care and End-of-Life Issues (16 papers), Prostate Cancer Treatment and Research (15 papers) and Renal cell carcinoma treatment (12 papers). Biren Saraiya collaborates with scholars based in United States, Netherlands and South Korea. Biren Saraiya's co-authors include Robert M. Arnold, Toby C. Campbell, Vicki A. Jackson, Elise C. Carey, Holly Yang, Eric A. Singer, Anthony L. Back, Tina Mayer, Isaac Yi Kim and Sinae Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Biren Saraiya

53 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Biren Saraiya United States 12 162 129 109 78 74 59 385
Michael Conlon Canada 8 112 0.7× 72 0.6× 130 1.2× 84 1.1× 132 1.8× 25 410
C. Louzado Canada 7 250 1.5× 96 0.7× 90 0.8× 50 0.6× 31 0.4× 11 442
Po‐Jung Su Taiwan 14 239 1.5× 210 1.6× 83 0.8× 40 0.5× 38 0.5× 47 534
Margaret McJannett Australia 10 138 0.9× 105 0.8× 240 2.2× 122 1.6× 29 0.4× 21 463
Danielle D. Durham United States 12 220 1.4× 102 0.8× 106 1.0× 62 0.8× 24 0.3× 33 419
Jeannette M. Day United States 8 269 1.7× 89 0.7× 87 0.8× 43 0.6× 27 0.4× 12 393
Oliver Higuera Spain 13 305 1.9× 54 0.4× 135 1.2× 50 0.6× 46 0.6× 40 480
Kirsten F. L. Douma Netherlands 13 143 0.9× 74 0.6× 36 0.3× 98 1.3× 43 0.6× 17 438
Elham Hedayati Sweden 12 165 1.0× 79 0.6× 111 1.0× 28 0.4× 49 0.7× 44 438
Guorong Wang China 13 100 0.6× 64 0.5× 65 0.6× 94 1.2× 105 1.4× 47 470

Countries citing papers authored by Biren Saraiya

Since Specialization
Citations

This map shows the geographic impact of Biren Saraiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biren Saraiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biren Saraiya more than expected).

Fields of papers citing papers by Biren Saraiya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biren Saraiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biren Saraiya. The network helps show where Biren Saraiya may publish in the future.

Co-authorship network of co-authors of Biren Saraiya

This figure shows the co-authorship network connecting the top 25 collaborators of Biren Saraiya. A scholar is included among the top collaborators of Biren Saraiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Biren Saraiya. Biren Saraiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Blair, Cindy K., Yong Lin, Shou‐En Lu, et al.. (2025). Identification of Symptom Profiles in Prostate Cancer Survivors. Oncology nursing forum. 52(2). 137–150.
3.
4.
Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations
5.
Sutera, Philip, Jongmyung Kim, Ritesh Kumar, et al.. (2024). PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer. The Prostate. 84(14). 1301–1308. 2 indexed citations
6.
Greene, Kathryn, et al.. (2023). Facilitating psychological adjustment for breast cancer patients through empathic communication and uncertainty reduction. Patient Education and Counseling. 114. 107791–107791. 15 indexed citations
7.
Pan, Elizabeth, Wanling Xie, Archana Ajmera, et al.. (2023). A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Molecular Cancer Therapeutics. 22(4). 511–518. 29 indexed citations
8.
Pfail, John, Biren Saraiya, Tina Mayer, et al.. (2023). Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?. Current Urology Reports. 24(7). 299–306. 1 indexed citations
9.
Jani, Chinmay, Wanling Xie, Archana Ajmera, et al.. (2023). A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.. Journal of Clinical Oncology. 41(16_suppl). TPS5110–TPS5110.
10.
Singer, Eric A., et al.. (2023). Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma. PubMed. 5(1). 5–12. 5 indexed citations
11.
12.
Tabakin, Alexandra L., et al.. (2022). Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 9(2). 32–38. 1 indexed citations
13.
Kim, Isaac Yi, Antonina Mitrofanova, Sukanya Panja, et al.. (2022). Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate International. 10(2). 75–79. 8 indexed citations
14.
Patel, Hiren V., Sinae Kim, Arnav Srivastava, et al.. (2022). Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(3). 296–296.e9. 11 indexed citations
15.
Umbehr, Martin, Adrian Wagg, Jodi Antonelli, et al.. (2022). Top Ten Tips Palliative Care Clinicians Should Know About Urological Care. Journal of Palliative Medicine. 26(2). 264–269. 3 indexed citations
16.
Grafova, Irina B., Patrick R. Clifford, Shawna V. Hudson, et al.. (2022). Disease and debt: Findings from the 2019 Panel Study of Income Dynamics in the United States. Preventive Medicine. 164. 107248–107248. 5 indexed citations
17.
Grafova, Irina B., Sharon L. Manne, Elisa V. Bandera, et al.. (2021). Financial hardship among cancer survivors in Southern New Jersey. Supportive Care in Cancer. 29(11). 6613–6623. 5 indexed citations
18.
Srivastava, Arnav, Zorimar Rivera‐Núñez, Sinae Kim, et al.. (2020). Impact of pathologic lymph node‐positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer. Cancer. 126(13). 2991–3001. 22 indexed citations
19.
Srivastava, Arnav, Hiren V. Patel, Sinae Kim, et al.. (2020). Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars and Original Investigations. 39(5). 247–257. 8 indexed citations
20.
Niglio, Scot A., Daniel M. Girardi, Amir Mortazavi, et al.. (2020). Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology. 38(15_suppl). 5039–5039. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Conlon Breakdown of academic impact, for papers by C. Louzado Breakdown of academic impact, for papers by Po‐Jung Su Breakdown of academic impact, for papers by Margaret McJannett Breakdown of academic impact, for papers by Danielle D. Durham Breakdown of academic impact, for papers by Jeannette M. Day Breakdown of academic impact, for papers by Oliver Higuera Breakdown of academic impact, for papers by Kirsten F. L. Douma Breakdown of academic impact, for papers by Elham Hedayati Breakdown of academic impact, for papers by Guorong Wang
Rankless by CCL
2026